Skip to main
  1. Stocks
  2. Arcturus Therapeutics
  3. Forecast
ARCT

Arcturus Therapeutics (ARCT) Stock Forecast & Price Target

Arcturus Therapeutics (ARCT) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Arcturus Therapeutics is supported by a differentiated RNA medicines platform whose LUNAR 2.0 delivery technology has shown roughly 38x to 40x higher protein expression in preclinical models, with KOSTAIVE’s full approval validating the company’s self-amplifying mRNA approach and strengthening the vaccine franchise. In OTC deficiency, updated Phase 2 data showed fasting ammonia reduced to or maintained within normal range and glutamine trending lower despite protein intake changes, while management’s plan to transition to ARCT-2601 with FDA alignment and a cleaner preclinical safety package improves the development path and potential convenience profile. The thesis is further reinforced by strategic optionality in cystic fibrosis, including Thermo Fisher support worth up to $40M in clinical manufacturing services and up to $40M in CRO services, which can reduce execution risk and preserve capital while multiple programs advance.

Bears say

Arcturus Therapeutics is facing a negative fundamental outlook because operating expenses and cash burn appear elevated, increasing the likelihood of equity issuances at less attractive valuations and repeated dilution. The company also carries meaningful clinical risk: the ARCT-810 data showed infusion-related reactions, limited interpretability from small and incomplete datasets, no clear biomarker trend, and a study that was terminated after Cohort 1 due to slow enrollment. Longer development timelines, potential formulation changes, regulatory hurdles from the FDA and EMA, and competition from gene-agnostic urea cycle approaches further cloud the path to commercialization and capital efficiency.

Arcturus Therapeutics (ARCT) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcturus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Arcturus Therapeutics (ARCT) Analyst Forecast & Price Prediction

Get the latest Arcturus Therapeutics (ARCT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Arcturus Therapeutics (ARCT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcturus Therapeutics (ARCT) Forecast

Analysts have given Arcturus Therapeutics (ARCT) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Arcturus Therapeutics (ARCT) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcturus Therapeutics (ARCT)


Arcturus Therapeutics (ARCT) Analyst Forecast & Price Prediction

Get the latest Arcturus Therapeutics (ARCT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Arcturus Therapeutics (ARCT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ARCT stock data and trends